A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Part of paid clinical trials in Miami, Florida.

Sponsor
Forma Therapeutics, Inc.
Study ID
NCT05568225
Phase
PHASE2
Status
Terminated

Conditions

  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk MDS.

Key Dates

Start date
Nov 15, 2022
Status verified
Oct 2025
Primary completion
Jul 15, 2024
Completion
Jul 15, 2024

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Etavopivat 400 mg QD daily
    Non-transfusion dependent (NTD), Low transfusion burden (LTB) , and High transfusion burden (HTB) patients

Primary Outcome Measure

Percentage of Participants With Hematologic Improvement- Erythroid (HI-E) Response for >=8 Weeks Within 24 Weeks of Etavopivat Treatment [ Time Frame: From Baseline to Week 24 ]

Locations (8)

FacilityCityStateZIPSite coordinators
University of Miami Hospital and ClinicsMiamiFlorida33136-
Ocala OncologyOcalaFlorida34474-
Cedars-Sinai Medical CenterPlainsboroNew Jersey08536-
Northwell HealthPlainsboroNew Jersey08536-
Northwestern Memorial HospitalPlainsboroNew Jersey08536-
The Ohio State University Medical CenterPlainsboroNew Jersey08536-
Columbia University Irving Medical CenterNew YorkNew York10032-
NYU Langone HealthNew YorkNew York10016-

Related coverage on Hipa.ai

Find similar trials in Miami, FL

By research site
University of Miami Hospital and Clinics· Miami, FLOcala Oncology· Ocala, FLCedars-Sinai Medical Center· Plainsboro, NJNorthwell Health· Plainsboro, NJNorthwestern Memorial Hospital· Plainsboro, NJThe Ohio State University Medical Center· Plainsboro, NJ